Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL, in patients with cancer

Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood-brain barrier

(2012) Julia Lemmen et al.   BRAIN RESEARCH

Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer

(2012) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

The Role of BCS (Biopharmaceutics Classification System) and BDDCS (Biopharmaceutics Drug Disposition Classification System) in Drug Development

(2012) Leslie Z. Benet   JOURNAL OF PHARMACEUTICAL SCIENCES

Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy

(2012) Mary Tomek et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Fucoxanthin Attenuates Rifampin-Induced Cytochrome P450 3A4 (CYP3A4) and Multiple Drug Resistance 1 (MDR1) Gene Expression Through Pregnane X Receptor (PXR)-Mediated Pathways in Human Hepatoma HepG2 and Colon Adenocarcinoma LS174T Cells

(2012) Cheng-Ling Liu et al.   Marine Drugs

BDDCS Applied to Over 900 Drugs

(2011) Leslie Z. Benet et al.   AAPS Journal

The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein

(2011) Meike Vogler et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Targeting apoptosis proteins in hematological malignancies

(2011) Nathalie Droin et al.   CANCER LETTERS

Rifampin Enhances the Glucose-Lowering Effect of Metformin and Increases OCT1 mRNA Levels in Healthy Participants

(2011) S K Cho et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH